134523-02-7

Basic information

• Product Name: atorvastatin potassium
• Synonyms: atorvastatin potassium
• CAS NO: 134523-02-7
• Molecular Weight: 596.74
• Mol File: 134523-02-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: atorvastatin potassium(CAS DataBase Reference)
• NIST Chemistry Reference: atorvastatin potassium(134523-02-7)
• EPA Substance Registry System: atorvastatin potassium(134523-02-7)

Safety Data

• Hazardous Substances Data: 134523-02-7(Hazardous Substances Data)

Upstream product

• 125971-95-1 tert-butyl (4R,6R)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-2,2-dimethyl-1,3-dioxane-4-acetate 
• 134395-00-9 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid t-butyl ester 
• 1119697-15-2 atorvastatin lactone 
• 125995-03-1 atorvastatin lactone 
• 134523-00-5 atorvastatin 

Downstream Products

• 125995-03-1 atorvastatin lactone 
• 134523-03-8 lipitor 

Relevant articles and documents

Method for purifying atorvastatin calcium intermediate

The atorvastatin calcium intermediate is subjected to hydrolysis reaction to obtain the reaction liquid of atorvastatin calcium intermediate. The reaction liquid is extracted with a stripping solvent and is separated and separated to obtain an aqueous pha

Preparation method of crystal form I atorvastatin calcium

The invention discloses a preparation method of crystal form I atorvastatin calcium. The method includes the steps of: preparation of atorvastatin ester; preparation of an atorvastatin salt; preparation of atorvastatin calcium; refining an atorvastatin ca

PRODRUG OF ATROVASTATIN BY CHOLESTEROL'S SYNTHESIS INHIBITORS

The present invention relates to atorvastatin prodrugs or pharmaceutically acceptable salts thereof. The compound of the present invention is hydrolyzed to atorvastatin in a body and allows atorvastatin to be maintained in a concentration effective in inhibiting the production of cholesterol for a long time. Further, the compound of the present invention can reduce side effects caused by an initial high concentration of atorvastatin in blood, thereby improving safety problems remarkably. Therefore, the compound of the present invention is effective in treating or preventing various diseases caused by excessive cholesterol such as hyperlipidemia, etc.